Back to Results

A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Child to Adult

Type of Study

Treatment

Location

University of Colorado Hospital

Principal Investigator
Theresa Medina,  MD

Theresa Medina, MD

Study ID

Protocol Number: 21-3431

More information available at ClinicalTrials.gov: NCT04985604

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers